Related Experiment Video
Updated: Mar 11, 2026
08:45
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
1.8K
Thrombocytopenia in chronic liver disease
1Department of Gastroenterology, Hepatology, Endocrinology and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Summary
Thrombocytopenia, or low platelet count, is common in chronic liver disease. Reduced liver production of thrombopoietin is a key cause, impacting platelet counts and recovery after liver transplant.
Area of Science:
- Hematology
- Hepatology
- Oncology
Background:
- Thrombocytopenia is a frequent complication in chronic liver disease (CLD), increasing bleeding risks during medical procedures.
- Pathophysiology involves hypersplenism, bone marrow suppression, and immune-mediated platelet destruction.
- The role of hypersplenism is debated due to limited platelet recovery after interventions.
Purpose of the Study:
- To elucidate the central mechanisms of thrombocytopenia in chronic liver disease.
- To highlight the role of thrombopoietin in platelet production and its reduction in advanced liver disease.
- To discuss the implications for liver transplantation and emerging treatments.
Main Methods:
- Review of existing literature on thrombocytopenia in chronic liver disease.
- Analysis of the role of thrombopoietin, a key cytokine produced by the liver.
- Evaluation of the impact of liver disease severity on thrombopoietin levels and platelet counts.
Main Results:
- Reduced liver cell mass in advanced CLD leads to decreased thrombopoietin production.
- Lower thrombopoietin levels result in impaired bone marrow thrombopoiesis and peripheral thrombocytopenia.
- Successful liver transplantation restores thrombopoietin production and platelet counts.
Conclusions:
- Reduced hepatic thrombopoietin production is a primary driver of thrombocytopenia in advanced chronic liver disease.
- Thrombocytopenia management may involve addressing thrombopoietin levels.
- New therapies targeting thrombopoietin activity are under development.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
307
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
247
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247
01:24Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
01:24Chronic Pancreatitis I: Introduction
830
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
830
01:26Diseases of the Liver and Gallbladder
2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K